Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 2,102 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable saline Clear all

Conditions: Postoperative Pain
Interventions: HTX-011, Placebo, HTX-002, Bupivacaine HCI (Marcaine), HTX-011A, HTX-011B, HTX-009; Drug
Lead sponsor: Heron Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: Anaheim, California • Houston, Texas

Conditions: Renal Insufficiency, Renal Impairment
Interventions: sugammadex; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Healthy
Interventions: LY3471851, Placebo; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Tennis Elbow, Lateral Epicondylitis
Interventions: Placebo Injection, Physical Therapy, Corticosteroid Injections, Prolotherapy; Drug · Behavioral
Lead sponsor: Christine M. Kleinert Institute for Hand and Microsurgery; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Knee Osteoarthritis
Interventions: Amniotic Suspension Allograft, Placebo; Biological · Drug
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years and older
Enrollment: 594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 41
States / cities: Birmingham, Alabama • Tempe, Arizona • La Mesa, California + 34 more

Conditions: Femoral Shaft Fracture, Tibial Shaft Fracture
Interventions: GIK solution, Isotonic Normal Saline Solution; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Squamous Cell Carcinoma in Situ
Interventions: STP705, Placebo Saline; Drug · Other
Lead sponsor: Sirnaomics; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Scottsdale, Arizona • Aventura, Florida • West Palm Beach, Florida + 4 more

Conditions: Femoroacetabular Impingement, Chondral Lesions
Interventions: Platelet-rich plasma (PRP), Saline; Biological · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Snakebite, Envenoming, Snake
Interventions: Varespladib intravenous form, varespladib-methyl- oral form, Placebo intravenous form, Placebo - oral form; Drug
Lead sponsor: Ophirex, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Phoenix, Arizona • Tucson, Arizona • Palm Springs, California + 7 more

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab pegol, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 50
States / cities: Huntsville, Alabama • Montgomery, Alabama • Gilbert, Arizona + 47 more

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Botulinum Toxin A (Allergan, Inc, Irvine CA), Placebo; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 13 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Pain
Interventions: Ketamine IV Infusion, Ketamine IV push; Drug
Lead sponsor: Alameda Health System; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Oakland, California

Conditions: Dental Pain
Interventions: Bupivacaine liposome, Placebo; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Terminally Ill, Histologically-confirmed Advanced Cancer, Pain, Intractable
Interventions: Substance P-Saporin; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: La Jolla, California • Dallas, Texas

Conditions: Ebola
Interventions: Ad26.ZEBOV, MVA-BN-Filo, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 974 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 7
States / cities: Mobile, Alabama • Tempe, Arizona • Lexington, Kentucky + 4 more

Conditions: Spasmodic Torticollis
Interventions: Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin, Physiologic saline; Drug · Other
Lead sponsor: Mentor Worldwide, LLC; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Prostate Cancer, Benign Prostatic Hyperplasia, Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS)
Interventions: BOTOX; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 50 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Placebo - Control, Experimental
Interventions: EXERCISE TRAINING WITH OR WITHOUT MEDICATION; Drug
Lead sponsor: Northern Arizona University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Flagstaff, Arizona

Conditions: Influenza
Interventions: FLUGEN 101.2 device; Device
Lead sponsor: FluGen Inc; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Melbourne, Florida

Conditions: Skin Diseases, Infectious
Interventions: Daptomycin, Standard of Care (SOC); Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 1 Year to 17 Years
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 22
States / cities: Birmingham, Alabama • Oakland, California • Orange, California + 18 more

Conditions: Urinary Catheter Blockage and Encrustation
Interventions: NVC-422, 0.2%, Sterile normal saline, 0.9%; Drug
Lead sponsor: NovaBay Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 8
States / cities: Downey, California • Naples, Florida • West Orange, New Jersey + 5 more

Conditions: Pain
Interventions: Botulinum Toxin Type A, Saline; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Healthy Volunteers, Obesity
Interventions: Ghrelin, Saline; Drug
Lead sponsor: Jenny Tong, MD, MPH; Other
Eligibility: 18 Years to 40 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hip Fractures
Interventions: Exparel, Sodium Chloride; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 55 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Lexington, Kentucky • Worcester, Massachusetts

Search by objective public record fields.

Pilot Herniorrhaphy Study for Postoperative Analgesia

Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105)

A Study of NKTR-358 (LY3471851) in Healthy Participants

Comparison of Conservative Methods for the Treatment of Lateral Epicondylitis: A Randomized, Prospective Study

A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee

MAGIK for Femoral/Tibial Shaft Fractures

A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC

Efficacy of PRP (Platelet Rich Plasma) Following Arthroscopic Microfracture of Chondral Lesions of the Hip

Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)

Dosing Flexibility Study in Patients With Rheumatoid Arthritis

Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis Suppurativa

Intravenous Sub-dissociative Dose Ketamine Injection Versus Infusion for Analgesia in the Emergency Department

Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction

A Phase 1 Study of Substance P-Saporin in Terminal Cancer Patients With Intractable Pain

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

PurTox (Botulinum Toxin Type A) for the Treatment of Adult Onset Spasmodic Torticollis/Cervical Dystonia

BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)

What is the Role of Type III/IV Muscle Afferents in Airway Resistance and Thermoregulatory Responses to Exercise?

Intracutaneous Delivery of Varied Dose Volumes of Saline

Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections

Study to Evaluate NVC-422 for Urinary Catheter Blockage and Encrustation

Subcutaneous Botulinum Toxin for Cutaneous Allodynia - Enriched Responder Trial

Effect of Ghrelin on Decision-Making

Randomized Controlled Trial for Exparel Hip Fracture